Naval G. Daver, MD introduces myelodysplastic syndrome (MDS), focusing on the typical disease course, role of biomarker testing and risk stratification.
Targeting CD47 in Higher-Risk Myelodysplastic Syndrome (MDS)
Dr. Daver reviews treatment goals and treatment options for patients with higher-risk MDS.
Subject-matter expert provides an overview of the CD47 pathway and shares how emergent trial data are impacting the MDS treatment landscape.
Dr. Daver anticipates how the MDS landscape will evolve over time, emphasizing the importance of adopting targeted therapies.
Advertisement
Advertisement
Trending on CancerNetwork
1
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
2
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
3
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
4
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
5
